Clinical Trials
20 trialsNCT06124157 2026-05-27
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07171203 2026-05-27
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
Phase 1 Recruiting
NCT06090669 2026-05-22
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07406633 2026-05-19
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Kumquat Biosciences Inc.
Phase 2 Recruiting
NCT04877522 2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT04307576 2026-05-05
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Karolinska University Hospital
Phase 3 Recruiting
NCT05152472 2026-04-24
ATEZOGIST
Centre Leon Berard
Phase 2 Recruiting
NCT05493215 2026-02-17
Imatinib TDM in GIST
University of Kentucky
Phase 2 Recruiting
NCT06655246 2026-02-05
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06889168 2026-01-21
LAMP-2
Columbia University
Phase 1 Recruiting
NCT04598009 2025-09-03
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
University of California, San Francisco
Phase 2 Recruiting
NCT05385549 2025-08-08
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Asan Medical Center
Phase 2 Recruiting
NCT04838041 2025-07-30
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
Phase 2 Recruiting
NCT05722795 2025-07-09
I-CONIC
Vastra Gotaland Region
Phase NA Recruiting
NCT06962254 2025-05-08
Imatinib and Trametinib for KRAS-mutated Solid Tumor
China Medical University Hospital
Phase 1 Recruiting
NCT03844360 2025-03-30
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Shandong University
Phase 4 Recruiting
NCT06119789 2025-03-26
MATRIX-Rare
Oslo University Hospital
Phase 2 Recruiting
NCT04423185 2025-02-11
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT05009927 2023-09-01
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)
Centre Leon Berard
Phase 2 Recruiting
NCT04933669 2021-10-12
ZJGIST-01
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting